Would you recommend adjuvant abemaciclib for ER+ HER2 neg inflammatory breast cancer who do not achieve pCR with neoadjuvant chemotherapy?

I would certainly consider it. It would be helpful to have additional information:

1. How many LN were positive at diagnosis?
2. What is Ki-67?
3. Grade--likely grade 3 for inflammatory
4. How much residual disease at surgery?

Though none has given definitive answers to assist, these factors could play roles in my decision. Based on the criteria for use of abemacilib, factors such as 4 + LN, 1-3 + LN, and grade 3 or > 5 cm disease or Ki-67 >20% would push me to use it, even though patients with inflammat...

Most studies exclude inflammatory breast cancer (IBC) not because the investigators think the treatment would not work in IBC but because they are afraid the inclusion of IBC would muddle their results. monarchE was designed for high-risk ER+/HER2- disease. And IBC is certainly a high-risk disease. Therefore, I would not hesitate to use adjuvant abemaciclib in IBC. IBC is almost always grade 3 with high Ki67 anyway. Tumor size is not relevant in IBC. If a T3 or higher meets the criteria, certain...